Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-848d4c4894-nr4z6 Total loading time: 0 Render date: 2024-05-10T15:46:34.229Z Has data issue: false hasContentIssue false

Chapter 24 - Contraceptive Choices for Women with HIV Infection

from Section 2A - Sexual and Reproductive Healthcare: Contraception

Published online by Cambridge University Press:  16 January 2024

By
Katarina Sedlecky ,
Gabriele S. Merki-Feld  and
Frans J. M. E. Roumen
Edited by
Johannes Bitzer  and
Tahir A. Mahmood
Johannes Bitzer
Affiliation:
University Women's Hospital, Basel
Tahir A. Mahmood
Affiliation:
Victoria Hospital, Kirkcaldy
Get access

Summary

Women account for more than half of the individuals infected with human immunodeficiency virus (HIV), and at particularly high risk are those aged 15–24 years [1]. In the era of combined antiretroviral treatment (ART), HIV has become a chronic manageable condition, and many more affected women can nowadays re-evaluate their reproductive choices, including childbearing and prevention of pregnancy [2].

Type
Chapter
Information
Textbook of Contraception, Sexual and Reproductive Health , pp. 165 - 169
Publisher: Cambridge University Press
Print publication year: 2024

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

UN Women. Facts and figures: HIV and AIDS. 2018. https://bit.ly/3wGpmsu.Google Scholar
World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: Recommendations for a public health approach. 2nd edition. Geneva: World Health Organization, 2016. www.who.int/hiv/pub/arv/arv-2016/en.Google Scholar
Amin, A. Addressing gender inequalities to improve the sexual and reproductive health and wellbeing of women living with HIV. J Int AIDS Soc. 2015;18(Suppl 5):20302.CrossRefGoogle ScholarPubMed
Sharma, M, Walmsley, SL. Contraceptive options for HIV-positive women: Making evidence-based, patient-centred decisions. HIV Med. 2015;16(6):329–36.CrossRefGoogle ScholarPubMed
Scarsi, KK, Darin, KM, Chappell, CA, Nitz, SM, Lamorde, M. Drug–drug interactions, effectiveness, and safety of hormonal contraceptives in women living with HIV. Drug Saf. 2016;39(11):1053–72.CrossRefGoogle ScholarPubMed
Scarsi, KK, Cramer, YS, Rosenkranz, SL et al. Antiretroviral therapy and vaginally administered contraceptive hormones: A three-arm, pharmacokinetic study. Lancet HIV. 2019;6(9):e601–e612.CrossRefGoogle ScholarPubMed
Nanda, K, Stuart, GS, Robinson, J et al. Drug interactions between hormonal contraceptives and antiretrovirals. AIDS. 2017;31(7):917–52.CrossRefGoogle ScholarPubMed
Hel, Z, Stringer, E, Mestecky, J. Sex steroid hormones, hormonal contraception, and the immunobiology of human immunodeficiency virus-1 infection. Endocr Rev. 2010;31(1):79–97.CrossRefGoogle ScholarPubMed
Morrison, CS, Hofmeyr, GJ, Thomas, KK et al. Effects of depot medroxyprogesterone acetate, copper intrauterine devices, and levonorgestrel implants on early HIV disease progression. AIDS Res Hum Retroviruses. 2020;36(8):632–40.CrossRefGoogle ScholarPubMed
Curtis, KM, Hannaford, PC, Rodriguez, MI et al. Hormonal contraception and HIV acquisition among women: An updated systematic review. BMJ Sex Reprod Health. 2020;46(1):8–16.CrossRefGoogle ScholarPubMed
Tepper, NK, Curtis, KM, Nanda, K, Jamieson, DJ. Safety of intrauterine devices among women with HIV: A systematic review. Contraception. 2016;94(6):713–24.Google ScholarPubMed
Todd, CS, Jones, HE, Langwenya, N et al. Safety and continued use of the levonorgestrel intrauterine system as compared with the copper intrauterine device among women living with HIV in South Africa: A randomized controlled trial. PLoS Med. 2020;17(5):e1003110.CrossRefGoogle ScholarPubMed
Lutalo, T, Musoke, R, Kong, X et al. Effects of hormonal contraceptive use on HIV acquisition and transmission among HIV-discordant couples. AIDS. 2013;27(Suppl 1):S27–34.CrossRefGoogle ScholarPubMed
Heffron, R, Donnell, D, Rees, H et al. Use of hormonal contraceptives and risk of HIV-1 transmission: A prospective cohort study. Lancet Infect Dis. 2012;12(1):19–26.CrossRefGoogle ScholarPubMed
Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial Consortium. HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: A randomised, multicentre, open-label trial. Lancet. 2019;394(10195):303–13.Google Scholar
World Health Organization. Medical eligibility criteria for contraceptive use. 5th edition. Geneva: World Health Organization, 2015.Google Scholar
Patel, RC, Bukusi, EA, Baeten, JM. Current and future contraceptive options for women living with HIV. Expert Opin Pharmacother. 2018;19(1):1–12.CrossRefGoogle ScholarPubMed
Hannaford, PC, Ti, A, Chipato, T, Curtis, KM. Copper intrauterine device use and HIV acquisition in women: A systematic review. BMJ Sex Reprod Health. 2020;46(1):17–25.CrossRefGoogle ScholarPubMed
Majeed, SR, West, S, Ling, KH, Das, M, Kearney, BP. Confirmation of the drug–drug interaction potential between cobicistat-boosted antiretroviral regimens and hormonal contraceptives. Antivir Ther. 2019;24(8):557–66.CrossRefGoogle ScholarPubMed
Agrati, C, Mazzotta, V, Pinnetti, C, Biava, G, Bibas, M. Venous thromboembolism in people living with HIV infection (PWH). Transl Res. 2020;S1931–5244(20):30174–2.Google Scholar
Hsue, PY, Waters, DD. HIV infection and coronary heart disease: Mechanisms and management. Nat Rev Cardiol. 2019;16(12):745–59.CrossRefGoogle ScholarPubMed
Patel, RC, Onono, M, Gandhi, M et al. A retrospective cohort analysis comparing pregnancy rates among HIV-positive women using contraceptives and efavirenzor nevirapine-based antiretroviral therapy in Kenya. Lancet HIV. 2015;2(11):e474–e482.CrossRefGoogle Scholar
Elliot, ER, Bisdomini, E, Penchala, SD et al. Pharmacokinetics (PK) of ethinylestradiol/levonorgestrel co-administered with atazanavir/cobicistat. HIV Res Clin Pract. 2019;23:1–10.Google Scholar
Trezza, C, Ford, SL, Gould, E et al. Lack of effect of oral cabotegravir on the pharmacokinetics of a levonorgestrel/ethinyl oestradiol-containing oral contraceptive in healthy adult women. Br J Clin Pharmacol. 2017;83(7):1499–1505.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×